Qiji Li

Qiji Li

Auto-generated profile, based on publicly available information

Qiji Li

Department of Orthopaedic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2015 in International Journal of Oncology
Verified
Journal Article
Closed access
MWMin Wang
Min Wang
DRDong Ren
Dong Ren
WGWei Guo
Wei Guo
SHShuai Huang
Shuai Huang
ZWZeyu Wang
Zeyu Wang
XPXinsheng Peng
Xinsheng Peng
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

28 October 2019 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
LYLiping Ye
Liping Ye
CLChuyong Lin
Chuyong Lin
XWXi Wang
Xi Wang
QLQiji Li
Qiji Li
YLYue Li
Yue Li
LSlibing Song
libing Song
Resistance to tamoxifen is a clinically major challenge in breast cancer treatment. Although downregulation of estrogen receptor‐alpha (ERα) is the dominant mechanism of tamoxifen resistance, the reason for ERα decrease during tamoxifen therapy remains elusive. Herein, we reported that Spalt‐like transcription factor 2 (SALL2) expression was significantly reduced during tamoxifen therapy through transcription profiling analysis of 9 paired primary pre‐tamoxifen‐treated and relapsed tamoxifen‐resistant breast cancer tissues. SALL2 transcriptionally upregulated ESR1 and PTEN through directly binding to the DNA promoters. By contrast, silencing SALL2 induced downregulation of ERα and PTEN and activated the Akt/mTOR signaling, resulting in estrogen‐independent growth and tamoxifen resistance in ERα‐positive breast cancer. Furthermore, hypermethylation of SALL2 promoter was found in tamoxifen‐resistant breast cancer. Importantly, in vivo experiments showed that DNA methyltransferase inhibitor‐mediated SALL2 restoration resensitized tamoxifen‐resistant breast cancer to tamoxifen therapy. These findings shed light on the mechanism of SALL2 in regulation of ER and represent a potential clinical signature that can be used to categorize breast cancer patients who may benefit from co‐therapy with tamoxifen and DNMT inhibitor.

1 August 2017 in Cancer Letters
Verified
Journal Article
Closed access
QLQiji Li
Qiji Li
LYLiping Ye
Liping Ye
XZXin Zhang
Xin Zhang
MWMin Wang
Min Wang
CLChuyong Lin
Chuyong Lin
XPXinsheng Peng
Xinsheng Peng

2 August 2016 in Oncology Reports
Verified
Journal Article
Closed access
SHSheng Huang
Sheng Huang
YTYubo Tang
Yubo Tang
XPXinsheng Peng
Xinsheng Peng
XCXingdong Cai
Xingdong Cai
QWQingde Wa
Qingde Wa
SHShuai Huang
Shuai Huang
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

13 July 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SHShuai Huang
Shuai Huang
QWQingde Wa
Qingde Wa
JPJincheng Pan
Jincheng Pan
XPXinsheng Peng
Xinsheng Peng
DRDong Ren
Dong Ren
YTYubo Tang
Yubo Tang
High avidity of bone metastasis is an important characteristic in prostate cancer (PCa). Downexpression of miR-133b has been reported to be implicated in the development, progression and recurrence in PCa. However, clinical significance and biological roles of miR-133b in bone metastasis of PCa remain unclear. Here we report that miR-133b is downregulated in PCa tissues and further decreased in bone metastatic PCa tissues. Downexpression of miR-133b positively correlates with advanced clinicopathological characteristics and shorter bone metastasis-free survival in PCa patients. Upregulating miR-133b inhibits invasion, migration in vitro and bone metastasis in vivo in PCa cells. Mechanistically, we find that miR-133b suppresses activity of TGF-β signaling via directly targeting TGF-β receptor I and II, which further inhibits bone metastasis of PCa cells. Our results further reveal that overexpression of REST contributes to miR-133b downexpression via transcriptional repression in PCa tissues. Importantly, silencing miR-133b enhances invasion and migration abilities in vitro and bone metastasis ability in vivo in REST-silenced PCa cells. The clinical correlation of miR-133b with TGFBRI, TGFBRII, REST and TGF-β signaling activity is verified in PCa tissues. Therefore, our results uncover a novel mechanism of miR-133b downexpression that REST transcriptionally inhibits miR-133b expression in PCa cells, and meanwhile support the notion that administration of miR-133b may serve as a rational regimen in the treatment of PCa bone metastasis.

1 May 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
QLQiji Li
Qiji Li
LYLiping Ye
Liping Ye
WGWei Guo
Wei Guo
MWMin Wang
Min Wang
SHShuai Huang
Shuai Huang
XPXinsheng Peng
Xinsheng Peng